छोड़कर सामग्री पर जाएँ

Blog

AstraZeneca India gets approval to market anti-diabetes drug

Dapagliflozin is the first and only anti-diabetic drug approved to significantly reduce the risk of sustained eGFR (estimated Glomerular Filtration Rate), cardiovascular deaths and hospitalisations due to heart failure in adults with progressive chronic kidney disease, the drug firm said.… और पढ़ें »AstraZeneca India gets approval to market anti-diabetes drug

MC Explains | What is an InvIT and why should investors have it in their portfolios?

InvITs list on the stock exchanges to raise capital for the purchase of a portfolio of operational infrastructure assets that are already producing consistent cash flows. It is like a hybrid product―with equity and fixed-income characteristics Read More Top 100… और पढ़ें »MC Explains | What is an InvIT and why should investors have it in their portfolios?

hi_INहिन्दी